Lexeo Therapeutics Says FDA Grants RMAT Designation To LX2020 Gene Therapy For PKP2-ACM Based On Interim Phase I/II HEROIC-PKP2 Data

Benzinga Newsdesk www.benzinga.com Positive 82.9%